tiprankstipranks
Trending News
More News >
Initiator Pharma A/S (SE:INIT)
:INIT
Sweden Market
Advertisement

Initiator Pharma A/S (INIT) Price & Analysis

Compare
0 Followers

INIT Stock Chart & Stats


INIT FAQ

What was Initiator Pharma A/S’s price range in the past 12 months?
Initiator Pharma A/S lowest stock price was kr3.15 and its highest was kr8.25 in the past 12 months.
    What is Initiator Pharma A/S’s market cap?
    Initiator Pharma A/S’s market cap is kr251.91M.
      When is Initiator Pharma A/S’s upcoming earnings report date?
      Initiator Pharma A/S’s upcoming earnings report date is Nov 21, 2025 which is in 67 days.
        How were Initiator Pharma A/S’s earnings last quarter?
        Initiator Pharma A/S released its earnings results on Aug 22, 2025. The company reported -kr0.101 earnings per share for the quarter, missing the consensus estimate of N/A by -kr0.101.
          Is Initiator Pharma A/S overvalued?
          According to Wall Street analysts Initiator Pharma A/S’s price is currently Overvalued. Get more investment ideas with TipRanks Premium
            Does Initiator Pharma A/S pay dividends?
            Initiator Pharma A/S does not currently pay dividends.
            What is Initiator Pharma A/S’s EPS estimate?
            Initiator Pharma A/S’s EPS estimate for its next earnings report is not yet available.
            How many shares outstanding does Initiator Pharma A/S have?
            Initiator Pharma A/S has 68,452,890 shares outstanding.
              What happened to Initiator Pharma A/S’s price movement after its last earnings report?
              Initiator Pharma A/S reported an EPS of -kr0.101 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went up 4.348%.
                Which hedge fund is a major shareholder of Initiator Pharma A/S?
                Currently, no hedge funds are holding shares in SE:INIT

                Company Description

                Initiator Pharma A/S

                Initiator Pharma A/S, a clinical stage life science company, develops drugs targeting unmet medical needs within the central and peripheral nervous system. It develops IP2018, a monoamine reuptake inhibitor for the treatment of psychogenic erectile dysfunction; IPED2015 to treat patients suffering from organic erectile dysfunction; and IPTN2021 for targeting an orphan drug indication in severe neuropathic pain. The company's pre-clinical stage candidates include IPNP2015 for the treatment of chronic pain; and IPDP2015 for depression. Initiator Pharma A/S was incorporated in 2016 and is headquartered in Copenhagen, Denmark.

                Initiator Pharma A/S (INIT) Earnings & Revenues

                Similar Stocks
                Company
                Price & Change
                Follow
                Medivir AB
                Isofol Medical AB
                Xintela AB
                Modus Therapeutics Holding AB
                Active Biotech AB
                Popular Stocks
                What am I Missing?
                Make informed decisions based on Top Analysts' activity
                Know what industry insiders are buying
                Get actionable alerts from top Wall Street Analysts
                Find out before anyone else which stock is going to shoot up
                Get powerful stock screeners & detailed portfolio analysis